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Abstract 
Background: Resistance to anti-tuberculosis (TB) drugs is a global 
problem. Previous studies showed that the prevalence of primary 
MDR-TB is higher and has been increasing. The purpose of this study 
was to determine the primary drug resistance in strains isolated from 
patients with smear-positive of the new cases to anti-TB drugs. 
Methods: In this cross-sectional study, 266 smear positive pulmonary 
TB Iranian patients were enrolled during the April 2011 and March 
2012. Drug Susceptibility Testing (DST) of M. tuberculosis isolates to 
the first-line drugs, isoniazid, rifampicin, ethambutol, and 
streptomycin, were performed by the proportion method using 
conventional Lowenstein-Jensen (L-J) medium. 
Results: The average age was 48.4±21.3 years, and 56.5 percent were 
male. In this study, out of 266 pulmonary TB suspects studied, 
susceptibility testing was performed for 189 isolates. Resistance to at 
least one drug was present in 11.1% (21/189) of cases. Resistance 
among newly diagnosed patients was most common for streptomycin, 
and MDR prevalence rates (resistant to ISONIAZID and RIFAMPIN) 
among these patients were 2.1%. 
Conclusions: Our finding suggests that the incidence of MDR 
tuberculosis in high TB burden settings stresses the need for drug 
susceptibility testing to be done for every patient who is culture positive 
for Mycobacterium tuberculosis. 
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Introduction 
Tuberculosis (TB) is a top infectious disease killer 
worldwide. In 2014, 9.6 million people fell ill with TB and 1.5 
million died from the disease. Over 95% of TB deaths occur in 
low- and middle-income countries, and it is among the top five 
causes of death for women aged 15 to 44. Globally in 2014, an 
estimated 480,000 people worldwide developed MDR-TB. It is 
estimated that about 9.7% of these cases were XDR-TB.1 
Mycobacterium tuberculosis, the bacterium that causes 
tuberculosis, is spread in airborne droplets when people with 
the disease cough or sneeze and usually infects the lungs 
(pulmonary tuberculosis).2 The characteristic symptoms of 
tuberculosis are a persistent cough, weight loss, and night 
sweats.3 Tuberculosis can be cured by taking several powerful 
antibiotics regularly for at least six months. The standard 
treatment for tuberculosis comprises an initial intensive phase 
lasting two months during which four antibiotics are taken 
daily followed by a four-month continuation phase during 
which two antibiotics are taken.4 
The emergence over the past two decades of multidrug-
resistant tuberculosis, or tuberculosis caused by strains of M. 
tuberculosis that are resistant to ISONIAZID and RIFAMPIN, 
with or without resistance to other agents, has greatly 
complicated efforts to control the global tuberculosis 
epidemic.5 
Gorgan is in the center of Golestan Province in northern 
Iran, southeast of the Caspian Sea.6 Due to its geographical 
position and vicinity to countries with a high incidence of TB 
and because it accepts immigrants, Golestan province at the 
northern part of country is one of the most infested provinces 
of the country. Today, drug resistance is considered as a serious 
problem in TB control programs in most countries. The risk of 
first-line treatment multi-drug-resistant tuberculosis (MDR-TB) 
and second-line treatment extensive-drug-resistant tuberculosis 
(EDR-TB) is considered a big problem in TB control. 
Therefore, understanding the prevalence of primary MDR-TB 
may help in the control and management of this disease. The 
current study aimed to determine the primary drug resistance 
strains isolated from patients with smear-positive of new cases 
to anti-TB drugs in Golestan in Northeast Iran. 
Materials and Methods  
In this cross-sectional study, which was conducted in 
Golestan province during 2011–2012, we determined initial 
drug resistance in smear-positive pulmonary TB patients (new 
cases) and their resistance pattern. 
The population study included all new smear-positive 
pulmonary TB patients who came to health center of Gorgan 
County. Patients whose direct sputum smear microscopy test 
were positive (at least two positive sputum smear) and had not 
already received anti-TB treatment or less than one week had 
passed from initiation of their TB treatment entered the study. 
Extra pulmonary TB cases were excluded from the study. 
The method of sampling was simple random. Demographic 
information including age, sex, place of residence, level of 
education, level of monthly income, patient’s inmate records, 
and the initial sputum positivity rating were recorded on a 
questioner. 
To culture samples on Lowenstein-Jensen medium, all 
samples were initially decontaminated using Petroff’s method.7 
Also, acid-fast staining was performed using the Ziehl–Neelsen 
method.4 Since the aim of this study is to determine initial drug 
susceptibility in patients infected with pulmonary TB induced 
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by M. tuberculosis strains (MTB), the species of strain isolated 
from sample was determined by using biochemical tests. 
Different tests, such as the niacin test, the nitrate reduction test, 
and thermostable catalase (68°C), were used to determine 
species.8 The isolates obtained were subjected to the drug 
susceptibility test (DST) by proportion method. This method is 
the gold standard and is confirmed by World Health 
Organization (WHO) and Clinical and Laboratory Standards 
Institute (CLSI). The proportional method was performed 
according to the method of Canetti, Rist, and Grosset.9 
This method is performed on strains for first- and second-
line drugs and needs at least three to four weeks incubation.9-11 
The proportional method is based on the estimation of growth 
or no growth of an M. tuberculosis strain in the presence of a 
single “critical concentration” of one drug. The critical 
concentration of an antituberculous drug represents the lowest 
concentration of the drug in the medium that indicates 
clinically relevant resistance if growth is observed.11 
Susceptible wild-type strains are inhibited by this 
concentration. Resistance is established if over 1% of the 
bacterial population of a strain is able to grow. Although these 
techniques are widespread and have been used for a long time, 
a low reproducibility of the procedures due to poor 
standardization is sometimes reported. Different levels of 
reliability can be observed between the different drugs tested. 
Proficiency testing for DST is implemented in the 
Supranational Reference Laboratory Network, which was 
established by the WHO and IUATLD. Results from nine 
rounds of proficiency testing carried out between 1994 and 
2002 showed higher sensitivities and specificities for INH and 
rifampicin (RMP) than for ethambutol (EMB) and 
streptomycin (SM) testing (cumulative sensitivities: 99% for 
INH, 97% for RMP, 91% for SM, and 89% for EMB; 
cumulative specificities: 98% for INH, 97% for RMP, and 94% 
for both EMB and SM).11 
Obtained information was entered into version 16 of the 
SPSS application (SPSS Inc., Chicago, IL, USA) and was 
analyzed based on descriptive and analytical statistics. In this 
study, the confidence interval was 95%, and P < 0.05 was 
considered significant. 
Results 
Two-hundred sixty-six patients were eligible for the study, 
and an antibiogram test was performed on 214 of them. Out of 
these, the antibiogram test of samples from 189 patients was 
successful in terms of performance, such that from 214 test 
cases, 10 cases were non-tuberculosis mycobacterium (NTB), 
and 15 cases led to failure of bacteria growth in antibiogram 
control medium (failed). Out of 189 successful antibiogram 
tests, 12 patients did not come back after samples were sent, 
and their demographic information was not recorded, and 
finally these cases were announced missing (6.3% missing 
data). Figure 1 shows the schematic view of the study plan and 
the number of people omitted from the study and the reason for 
their omission. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure: Schematic view of study plan.
Total number of patients whose demographic data 
have been reported in this study: 177 persons 
The number of patients who didn’t come back after their 
samples were sent and their susceptibility was determined 
and their demographic data were not recorded: 12 persons 
 
The number of patients whose samples 
were susceptible to drug: 168 persons 
 
The number of patients whose samples 
were resistant to drug: 21 persons 
 
Cases that their culture results were 
non-tuberculosis Mycobacterium 
(NTB): 10 persons 
 
Cases that antibiogram was 
performed for them: 214 persons 
Smear positive cases with 
contaminated culture medium 
omitted from study: 30 persons 
 
Smear positive cases with 
negative culture result omitted 
from study: 22 persons 
Total number of patients qualified 
to enter the study: 266 persons 
 
Cases with positive culture results, but bacilli have not 
grown on control culture media after antibiogram 
(Failed) and omitted from study: 15 persons 
 
The number of patients whose antibiogram 
tests were successful: 189 persons 
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The mean age of the patients was 48.4±21.3. All of the 
patients were new cases, and 56.5% of the patients were male. 
Only 2.8% of patients were non-Iranian and 21.5% of patients 
had a previous history of imprisonment. Other demographic 
information of patients has been given in Table 1.  
Of the 189 strains, 168 (88.9%) were sensitive to all drugs 
tested, and 21 (11.1%) were resistant to one or more drugs, as 
shown in Table 2. Among 189 isolates, resistance to a single 
drug was observed in 14 (7.4%) isolates, two drugs in two 
(1.05%) isolates, three drugs in three (1.56%) isolates, and four 
drugs in two (1.05%) isolates. MDR (resistance to both RIF 
and INH) was observed in four (2.1%) isolates. 
The association between age (P = 0.71), sex (P = 0.59) and 
drug-resistance were (chi square test and independent samples 
t-test) found to be insignificant.  
Discussion 
The present study showed that, out of 189 patients, 21 
patients (11.1%) were resistant to one or more drugs and this 
resistance can be against one, two, or more drugs 
simultaneously, while the rest of the patients (88.9%) were 
susceptible to antibiotics. It is to mention that four patients 
(2.1%) were resistant to rifampin and isoniazid (MDR) at the 
same time. The prevalence of primary drug resistance observed 
in different studies from India was found to be about 18.8% 
(7.9%–27.1%).12 
Abbassi’s study in Golestan province, showed that, in 260 
patients infected with TB, 31, 9, and 2 patients were still 
sputum smear-positive, respectively, after the end of second 
month of treatment, at the beginning of fifth month of 
treatment, and after the implementation of second phase of 
treatment, which after antibiogram it was determined that only 
one patient was resistant to rifampin and isoniazid, and another 
patient was resistant to all drugs, which translates into very low 
prevalence of drug-resistance (less than 0.5%). Prevalence of 
initial anti-TB drug-resistance is increasing, and this can have 
undesirable effects on the treatment of TB patients.13 
Peymani’s study, which was conducted on TB patients in 
Tabriz-Iran in 2011, showed that only one incidence of multi-
drug-resistance had been determined, and that the level of 
resistance was low in Tabriz province;14 therefore, the rate of 
negative-sputum increase in patients is within the expected 
level. The scourge of drug resistance in the world and 
possibility of diagnosis in our country (Iran) show the necessity 
of screening and proper treatment to improve the status-quo.15 
Also, findings of a very large research program conducted in 
36 countries to examine anti-TB drug-resistance showed that 
American countries, such as the Dominican Republic, have 
high level of resistance; the cause of this prevalence can be 
attributed to poorness of the TB control system, although 
immigration can also be a reason.16 Also, in African countries 
with very high level of HIV infection and poorness of TB 
control system, the level of resistance was unexpectedly very 
low; the reason why the resistance prevalence is low could be 
attributed to the treatment implemented under supervision of 
the health system. In western European countries, prevalence of 
multi-drug-resistance is very low and has been reported around 
1%, but in some countries, such as Span, 28% of TB patients 
have HIV infection simultaneously.17 In Asian countries, in 
which TB is an endemic disease, resistance prevalence is 
different; in some countries, like Korea, prevalence is very low, 
and in some countries, like India, multi-drug-resistance has 
been reported 13.3%.18 
A study was conducted to determine percentage of drug-
resistance in pulmonary TB patients in Istanbul and was 
compared to research conducted in Iran and other countries 
showed that 91 tuberculosis mycobacterium strains were 
isolated from sputum of patients suspected to have pulmonary 
TB as determined by standard the method. Susceptibility of 
isolated strains to four main anti-TB drugs, that is isoniazid, 
rifampin, ethambutol, and streptomycin, was examined by the 
indirect proportional method using Lowenstein-Jensen culture 
medium. The general resistance level was 44%. The highest 
level of initial resistance was 21.1% to streptomycin and after 
that was 15.8% to isoniazid, 5.3% to rifampin, and 2.6% to 
ethambutol. The level of initial MDR (multi-drug resistance) 
was 2.6%. Maximum secondary resistance was 33.3% to 
isoniazid and after that was 28.6% to streptomycin, 23.8% to 
rifampin, and 14.3% to ethambutol. The level of secondary 
MDR was 11.9%.15 
In another study, the goal was to demonstrate the 
tuberculosis mycobacterium resistance pattern to four anti-TB 
 
Table 1:  Frequency and percentage of demographic variables in initial 
drug-resistance smear positive pulmonary TB patients (new case), factors 
affecting it, and their antibiotic resistance in Golestan province in 2011–
2012. 
Variable Frequency Percentage 
Gender 100 56.5 
- Male 
- Female  
77 43.5 
Education   
- Elementary 
- Middle school 
- High school 
- Postgraduate 
- other 
62 35 
24 13.6 
12 6.8 
9 5.1 
70 39.5 
Marriage status   
- Single 
- Married 
- Widow 
- Divorcee 
- other 
43 24.3 
90 50.8 
35 19.8 
7 4 
2 1.1 
Occupation   
- Worker 
- Retired 
- Technical/Self-employed 
- Unemployed/Housekeeper 
- 0ther 
46 26 
10 5.6 
7 4 
96 54.2 
18 10.6 
Income status   
- Sufficient 
- Partially sufficient 
- Insufficient 
42 23.7 
47 26.6 
88 49.7 
Ethnicity   
- Fars 
- Sistanian 
- Turkoman 
- Other 
54 30.5 
71 40.1 
21 11.9 
31 17.6 
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 drugs in children infected with pulmonary TB. Among 350 
children (0–15 years of age) with confirmed TB, seven patients 
had resistance to at least one of the anti-TB drugs. Among 
these seven children, six patients were Afghan refugees and 
one person was Iranian. In this group, 85.7% showed resistance 
to RMP, 4.71% to INH, 1.57% to SM, and 28.6% to EMB. 
Also, 28.5% showed resistance to all four anti-TB drugs, RMP, 
EMB, SM, and INH, 2.14% to three drugs, INH, SM, and 
RMP, 5.28% to two drugs, RMP and INH, and 2.14% to RMP 
and 14.2% to SM. In this study, it was demonstrated that 14% 
of patients with Fars ethnicity, 9% of patients with Sistanian 
ethnicity, and 8.4% of patients with Turkoman ethnicity were 
resistant to TB. Also, 21% of individuals with inmate records 
had one resistance type.19 
The point of this study was to estimate the incidence of 
MDR tuberculosis in patients with smear-positive of the new 
cases. There are several limitations in our study. The study was 
limited exclusively to patients of one heath center of Golestan 
province and not the whole community. More studies are 
needed to investigate the incidence of MDR tuberculosis in 
other studies population. 
The incidence of MDR tuberculosis in high TB burden 
setting stresses the need for drug susceptibility testing to be 
done for every patient who is culture positive for M. 
tuberculosis. In addition, early diagnosis may prevent the 
therapy with inappropriate regimens and improve prognosis 
from causing MDR tuberculosis strains to develop additional 
resistance, reduce transmission, and manage drug-resistant TB. 
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